logo
Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137
rus
русский
eng
english

Site search



Correspondence address
310 Mira Street, Stavropol, Russia, 355017

Tel
+7 865 2352511, +7 865 2353229.

E-mail
medvestnik@stgmu.ru

Problem of comorbid course of chronic obstructive pulmonary disease and peripheral atherosclerosis

[Reviews]
Stanislav Nikolaevich Kotlyarov; Igor Suchkov; Oleg Uryasev;

The analysis of literature data on the clinical relationship between chronic obstructive pulmonary disease (COPD) and peripheral atherosclerosis was carried out. It has been shown that COPD is heterogeneous in clinical manifestations, including the nature of the comorbid course of peripheral atherosclerosis. Data on the pathophysiological mechanisms that determine the nature of the joint course of diseases, clinical predictors that determine the prognosis are given.

Download

References:
1. Gajnitdinova V. V., Avdeev S. N., Neklyudova G. V., Nuralieva G. S., Bajtemerova I. V. Vliyanie soputstvuyushhix serdechno-sosudisty`x zabolevanij na techenie i prognoz xronicheskoj obstruktivnoj bolezni legkih. Pulmonologiya. – Pulmonology. 2019;29(1):35-42. (In Russ.). https://doi.org/10.18093/0869-0189-2019-29-1-35-42
2. Roth G. A., Mensah G. A., Johnson C. O., Addolorato G., Ammirati E. [et al.]. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study [published correction appears in J. Am. Coll. Cardiol. 2021 Apr. 20;77(15):1958-1959]. J. Am. Coll. Cardiol. 2020;76(25):2982-3021.
3. Morgan A. D., Zakeri R., Quint J. K. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther. Adv. Respir. Dis. 2018;12:1-16. https://doi.org/10.1177/1753465817750524
4. Galani J., Mulder H., Rockhold F. W., Weissler E. H., Baumgartner I. [et al.]. Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2021;16:841-851. https://doi.org/10.2147/COPD.S292978
5. Brusselle G., Bracke K., De Pauw M. Peripheral Artery5. Brusselle G., Bracke K., De Pauw M. Peripheral Arter Disease in Patients with Chronic Obstructive Pulmonary Disease. Am. J. Respir. Crit. Care Med. 2017;195(2):148-150. https://doi.org/10.1164/rccm.201608-1712ED
6. Portegies M. L. P., Lahousse L., Joos G. F., Hofman A., Koudstaal P. J. [et al.]. Chronic obstructive pulmonary disease and the risk of stroke: the Rotterdam Study. Am. J. Respir. Crit. Care Med. 2016;193:251-258. https://doi.org/10.1164/rccm.201505-0962OC
7. Terzikhan N., Lahousse L., Verhamme K. M. C., Franco O. H., Ikram M. A. [et al.]. COPD is associated with an increased risk of peripheral artery disease and mortality. ERJ Open Research. 2018;4:00086-2018. https://doi.org/10.1183/23120541.00086-2018
8. Keller K., Hobohm L., Münzel T., Ostad M. A., Espinola- Klein C. Impact of chronic obstructive pulmonary di sease on the outcomes of patients with peripheral artery disease. Respiratory Medicine. 2019;147:1-6. https://doi.org/10.1016/j.rmed.2018.12.010
9. Lin M. S., Hsu K. Y., Chen Y. J., Chen C. R.., Chen C. M. [et al.]. Prevalence and risk factors of asymptomatic peripheral arterial disease in patients with COPD in Taiwan. PLoS One. 2013;8:e64714. https://doi.org/10.1371/journal.pone.0064714
10. Pecci R., De La Fuente Aguado J., Sanjurjo Rivo A. B., Sanchez Conde P., Corbacho Abelaira M. Peripheral arterial disease in patients with chronic obstructive pulmonary disease. Int. Angiol. 2012;31(5):444-453.
11. Houben-Wilke S., Jörres R. A., Bals R., Franssen F. M., Gläser S. [et al.]. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am. J. Respir. Crit. Care Med. 2017;195:189-197. https://doi.org/10.1164/rccm.201602-0354OC
12. Sartipy F., Sigvant B., Lundin F., Wahlberg E. Ten Year Mortality in Different Peripheral Arterial Disease Stages: A Population Based Observational Study on Outcome. Eur. J. Vasc. Endovasc. Surg. 2018;55(4):529-536. https://doi: org/10.1016/j.ejvs.2018.01.019
13. Hicks C. W., Yang C., Ndumele C. E., Folsom A. R., Heiss G. [et al.]. Associations of Obesity With Incident Hospitalization Related to Peripheral Artery Disease and Critical Limb Ischemia in the ARIC Study. J. Am. Heart Assoc. 2018;7(16):e008644. https://doi.org/10.1161/JAHA.118.008644
14. Nizov A. A., Yermachkova A. N., Abrosimov V. N., Ponomareva I. B. Kompleksnaya otsenka stepeni tyazhesti KhOBL na ambulatorno-poliklinicheskom priyeme. Rossysky mediko-biologichesky vestnik im. akademika I. P. Pavlova. – Russian Medical and Biological Bulletin named after Academician I. P. Pavlov. 2019;27(1):59-65. (In Russ.). https://doi.org/10.23888/PAVLOVJ201927159-65
15. Franssen F. M. E., Soriano J. B., Roche N., Bloomfield P. H., Brusselle G. [et al.]. Lung function abnormalities in smokers with ischemic heart disease. Am. J. Respir. Crit. Care Med. 2016;194:568-576. https://doi.org/10.1164/rccm.201512-2480OC 16. Vanfleteren L. E., Spruit M. A., Groenen M. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2013;187:728-735. https://doi.org/10.1164/rccm.201209-1665OC
17. Burgel P. R., Sethi S., Kim V. Chronic obstructive pulmonary disease phenotypes. Past, present, and future. Ann. Am. Thorac. Soc. 2015;12(3):289-290. https://doi.org/10.1513/AnnalsATS.201501-011ED
18. Hersh C. P., Make B. J., Lynch D. A., Barr R. G., Bowler R. P. [et al.]. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm. Med. 2014;14:164. https://doi.org/10.1186/1471-2466-14-164
19. Elrefai A. W., Alsayyad M. M., Dawood E. M. A. Pulmonary emphysema and atherosclerosis: association or syndrome? Egypt. J. Radiol. Nucl. Med. 2020;51:211. https://doi.org/10.1186/s43055-020-00319-7
20. Schivo M., Albertson T. E., Haczku A., Kenyon N. J., Zeki A. A. [et al.]. Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease. J. Investig. Med. 2017;65(6):953-963. https://doi:10.1136/jim-2016-000358
21. Enriquez J. R., Parikh S. V., Selzer F., Jacobs A. K., Marroquin O. [et al.]. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Chest. 2011;140:604-610. https://doi.org/10.1378/chest.10-2644
22. Visseren F. L. J., Mach F., Smulders Y. M, Carballo D., Koskinas K. C. [et al.]. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Europ. Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484
23. Camiciottoli G., Bigazzi F., Magni C. Prevalence of comorbidities according to predominant phenotype and severity of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2016;11:2229-2236. https://doi.org/10.2147/COPD.S111724
24. Takahashi S., Betsuyaku T. The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries. Respir. Investig. 2015;53:259-270. https://doi.org/10.1016/j.resinv.2015.05.005
25. Ogawa E., Nakano Y., Ohara T., Muro S., Hirai T. [et al.]. Body mass index in male patients with COPD: correlation with low attenuation areas on CT. Thorax. 2009;64:20-25. https://doi.org/10.1136/thx.2008.106674
26. McDonald M.-L. N., Wouters E. F. M., Rutten E., Casaburi R., Rennard S. I. [et al.]. It’s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respir. Resear. 2019;20:100. https://doi.org/10.1186/s12931-019-1073-3
27. Wang C., Xu J., Yang L., Xu Y., Zhang X. [et al.]. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391:1706-1717. https://doi.org/10.1016/S0140-6736(18)30841-9
28. Stoll P., Foerster S., Virchow J.C., Lommatzsch M. Overweight is a predictor of long-term survival in hospitalized patients with exacerbations of COPD. Respir. Med. 2016;116:59-62. https://doi.org/10.1016/j.rmed.2016.05.016
29. Wu Z., Yang D., Ge Z., Yan M., Wu N. [et al.]. Body mass index of patients with chronic obstructive pulmonary disease is associated with pulmonary function and exacerbations: a retrospective real world research. J. Thorac. Dis. 2018;10(8):5086-5099. https://doi.org/10.21037/jtd.2018.08.67
30. Shpagina O. V., Bondarenko I. Z. «Paradoks ozhireniya» – eshche odin vzglyad na problemu serdechno-sosudistyh zabolevanij. Ozhirenie i metabolism. – Obesity and metabolism. 2013;4:1-7. (In Russ.). https://doi.org/10.14341/OMET201343-9
31. Gupta S. S., Gothi D., Narula G., Sircar J. Correlation of BMI and oxygen saturation in stable COPD in Northern India. Lung India. 2014;31:29-34. https://doi.org/10.4103/0970-2113.125891
32. Wingårdh A. S. L., Göransson C., Larsson S., Slinde F., Vanfleteren L. E. G. W. Effectiveness of Energy Conservation Techniques in Patients with COPD. Respiration. 2020;99:409-416. https://doi.org/10.1159/000506816
33. Assal H. H., Kamal E. Body mass index and its relation to GOLD stage in chronic obstructive pulmonary disease patients. Egypt. J. Chest Dis. & Tub. 2016;65(2):411-414. https://doi.org/10.1016/j.ejcdt.2016.01.002
34. Narsale A. A., Carson J. A. Role of interleukin-6 in cachexia: therapeutic implications. Curr. Opin. Support. Palliat. Care. 2014;8(4):321-327. https://doi.org/10.1097/SPC.0000000000000091
35. Patel H. J., Patel B. M. TNF-α and cancer cachexia: Molecular insights and clinical implications. Life Sci. 2017;170:56-63. https://doi.org/10.1016/j.lfs.2016.11.033
36. Lakhdar R., Rabinovich R. A. Can muscle protein metabolism be specifically targeted by nutritional support and exercise training in chronic obstructive pulmonary disease? J. Thorac. Dis. 2018;10(Suppl. 12):S1377-S1389. https://doi.org/10.21037/jtd.2018.05.81
37. Hlapčić I., Belamarić D., Bosnar M., Kifer D., Vukić Dugac A. [et al.]. Combination of systemic inflammatory biomarkers in assessment of chronic obstructive pulmonary disease: diagnostic performance and identification of networks and clusters. Diagnostics. 2020;10(12):1029. https://doi.org/10.3390/diagnostics10121029
38. Kotlyarov S. Analysis of differentially expressed genes and signaling pathways involved in atherosclerosis and chronic obstructive pulmonary disease. Biomolecular Concepts. 2022;13(1):34-54. https://doi.org/10.1515/bmc-2022-0001
39. Chen H., Li Z., Dong L., Wu Y., Shen H., Chen Z. Lipid metabolism in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2019;14:1009-1018. https://doi.org/10.2147/COPD.S196210
40. Coxson H. O., Chan I. H., Mayo J. R., Hlynsky J., Nakano Y. [et al.]. Early emphysema in patients with anorexia nervosa. Am. J. Respir. Crit. Care Med. 2004;170:748-752. https://doi.org/10.1164/rccm.200405-651OC
41. Hersh C. P., Make B. J., Lynch D. A., Barr R. G., Bowler R. P. [et al.]. Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus. BMC Pulm. Med. 2014;14:164. https://doi.org/10.1186/1471-2466-14-164
42. Elagizi A., Kachur S., Lavie C. J., Carbone S., Pandey A. [et al.]. An overview and update on obesity and the obesity paradox in cardiovascular diseases. Prog. Cardiovasc. Dis. 2018;61:142-150. https://doi.org/10.1016/j.pcad.2018.07.003
43. Horwich T. B., Fonarow G. C., Clark A. L. Obesity and the obesity paradox in heart failure. Prog. Cardiovasc. Dis. 2018;61:151-156. https://doi.org/10.1016/j.pcad.2018.05.005
44. Ludhwani D., Wu J. obesity paradox in peripheral arterial disease: results of a propensity match analysis from the National Inpatient Sample. Cureus. 2019;11(5):e4704. https://doi.org/10.7759/cureus.4704
45. Galal W., van Gestel Y. R. B. M., Hoeks S. E., Sin D. D., Winkel T. A. [et al.]. The obesity paradox in patients with peripheral arterial disease. Chest. 2008;134:925-930. https://doi.org/10.1378/chest.08-0418
46. Pacha H. M., Al-khadra Y., Darmoch F., Soud M., Kaki A. [et al.]. Association between underweight body mass index and in-hospital outcome in patients undergoing endovascular interventions for peripheral artery disease: a propensity score matching analysis. J. Endovasc. Ther. 2019;26(3):411-417. https://doi.org/10.1177/1526602819839046
47. Smulders L., van der Aalst A., Neuhaus E. D. E. T., Polman S., Franssen F. M. E., M. [et al.]. Decreased risk of COPD exacerbations in obese patients. COPD: J. Chronic Obst. Pulm. Dis. 2020;17(5):485-491. https://doi.org/10.1080/15412555.2020.1799963
48. Babak S. L., Gorbunova M. V., Malaysian A. G. Khronicheskaya obstruktivnaya bolezn legkikh. v kn.: Putevoditel vrachebnykh naznacheny: covremennoye rukovodstvo dlya praktikuyushchikh vrachey. M.: «Bionika Media», 2017. (In Russ.).
49. Yuan S., Bruzelius M., Damrauer S. M., Wolk A., Akesson A. Anti-inflammatory diet and incident peripheral artery disease: Two prospective cohort studies. Clin. Nutr. 2022;41(6):1191-1196. https://doi.org/10.1016/j.clnu.2022.04.002
50. Tschopp J., Dumont P., Hayoz D. True prevalence of COPD and its association with peripheral arterial disease in the internal medicine ward of a tertiary care hospital. Swiss. Med. Wkly. 2017;147:w14460. https://doi.org/10.4414/smw.2017.14460
51. Gajnitdinova V. V., Avdeev S. N. Remodelirovanie krupnyh perifericheskih arterij u bolnyh hronicheskoj obstruktivnoj boleznyu legkih i pri ee sochetanii s arterialnoj gipertenziej. Pulmonologiya. – Russian Pulmonology. 2015;25(1):50-57. (In Russ.). https://doi.org/10.18093/0869-0189-2015-25-1-50-57
52. Kotlyarov S. Diversity of lipid function in atherogenesis: a focus on ndothelial mechanobiology. Int. Molec. Sci. 2021;22(21):11545. https://doi.org/10.3390/ijms222111545
53. Bobryshev Y. V., Ivanova E. A., Chistiakov D. A., Nikiforov N. G., Orekhov A. N. Macrophages and their role in atherosclerosis: pathophysiology and transcriptome analysis. Biomed. Res. Int. 2016;2016:9582430. https://doi.org/10.1155/2016/9582430
54. Kalinin R. E., Suchkov I. A., Chobanyan A. A. Prospects for forecasting the course of obliterating atherosclerosis of lower limb arteries. Science of the young. – Eruditio Juvenium. 2019;7(2):274-282. (In Russ.). https://doi.org/10.23888/HMJ201972274-282
55. Riksen N. P. Trained immunity and atherosclerotic cardiovascular disease. Curr. Opin. Lipidol. 2019;30(5):395-400. https://doi.org/10.1097/MOL.0000000000000628
56. Flores-Gomez D., Bekkering S., Netea M. G., Riksen N. P. Trained immunity in atherosclerotic cardiovascular disease. arterioscler. Thromb. Vasc. Biol. 2021;41(1):62-69. https://doi.org/10.1161/ATVBAHA.120.314216
57. Bekkering S., Quintin J., Joosten L. A. B., van der Meer J. W., Netea M.G. [et al.]. Oxidized low-density lipoprotein induces long-term proinflammatory cytokine production and foam cell formation via epigenetic reprogramming of monocytes. Arterioscler. Thromb. Vasc. Biol. 2014;34(8):1731-1738. https://doi.org/10.1161/ATVBAHA.114.303887
58. van der Valk F. M., Bekkering S., Kroon J., van der Meer J. W. M., Netea M. G. [et al.]. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611-624. https://doi.org/10.1161/CIRCULATIONAHA.116.020838
59. Bekkering S., van den Munckhof I., Nielen T., Lamfers E., Dinarello C. [et al.]. Innate immune cell activation and epigenetic remodeling in symptomatic and asymptomatic atherosclerosis in humans in vivo. Atherosclerosis. 2016;254:228-236. https://doi.org/10.1016/j.atherosclerosis.2016.10.019
60. Belskikh E. S., Uryasyev O. M., Zvyagina V. I., Faletrova S. V. Issledovaniye okislitelnogo stressa i funktsii mitokhondry v mononuklearnykh leykotsitakh krovi u bolnykh s khronicheskim bronkhitom i s khronicheskoy obstruktivnoy boleznyu legkikh. Nauka molodykh. – Eruditio Juvenium. 2018;6(2):203-210. (In Russ.). https://doi.org/10.23888/HMJ201862203-210

Keywords: COPD, peripheral atherosclerosis, comorbidity


Founders:
Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy